araag2/HINT huggingface dataset:
Clinical trial NCT00459836 (phase 1, status: completed)
Conditions: unspecified adult solid tumor, protocol specific
ICD codes: H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, H10.509
Drugs: pr-104, docetaxel, gemcitabine hydrochloride
SMILES: CS(=O)(=O)OCCN(CCBr)C1=C(C=C(C=C1[N+]([O-])=O)[N+]([O-])=O)C(=O)NCCOP(O)(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed solid tumor malignancy

          -  Treatment with either docetaxel or gemcitabine hydrochloride in combination with an
             investigational agent is reasonable

          -  Measurable or evaluable disease

        PATIENT CHARACTERISTICS:

          -  ECOG performance status of 0-1

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 9.0 g/dL (red blood cell transfusion allowed)

          -  Bilirubin normal

          -  ALT and AST ≤ 2.5 times upper limit of normal (ULN)

          -  Creatinine ≤ 1.5 times ULN

          -  PT/INR or aPTT ≤ 1.1 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 30 days after
             completion of study therapy

          -  No evidence of any other significant medical disorder, including uncontrolled
             infection or infection requiring a concurrent parenteral antibiotic, or laboratory
             finding that, in the opinion of the investigator, would preclude study compliance

          -  No known HIV positivity

          -  No hepatitis B surface antigen positivity

          -  No hepatitis C positivity with abnormal liver function test

        PRIOR CONCURRENT THERAPY:

          -  No prior radiotherapy to > 25% of bone marrow

          -  No prior high-dose chemotherapy (including conditioning for either myeloablative or
             nonmyeloablative transplantation)

          -  No more than 3 prior chemotherapy regimens

          -  More than 4 weeks since prior major surgery

          -  More than 4 weeks since prior investigational or traditional anticancer therapy
             (including radiotherapy) (6 weeks for nitrosoureas and mitomycin C)

          -  The following medications/treatments are not permitted during the trial:

               -  Any other licensed or investigational anticancer treatment

               -  Prophylactic hematopoietic growth factors

               -  Irradiation therapy (palliative or therapeutic) unless given in the absence of
                  tumor progression

          -  Concurrent systemic steroids allowed provided the patient is on a stable dose for ≥ 2
             weeks prior to study treatment

          -  Concurrent androgen-deprivation therapy allowed
Clinical trial NCT00664625 (phase 1/phase 2, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: bms-791325, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Chronically infected with HCV genotype 1

          -  Treatment naive or treatment non-responders or treatment intolerant

          -  HCV RNA viral load of ≥10*5* IU/mL

          -  BMI 18 to 35 kg/m²

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness which is not stable or is not
             controlled with medication and not consistent with HCV infection

          -  Major surgery within 4 weeks of study drug administration and any gastrointestinal
             surgery that could impact the absorption of study drug

          -  Co-infection with HIV or HBV
Clinical trial NCT01209533 (early phase 1, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: iloprost
SMILES: [H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Age 18-60

          2. History of asthma controlled by inhaled rescue medication (albuterol, levalbuterol
             etc) and/or inhaled corticosteroids

          3. Ability to give informed consent

          4. Ability to perform pulmonary function tests

          5. Ability to tolerate the initial Ventavis inhalation

          6. Ability to comply with the study protocol

        Exclusion Criteria:

          1. Cigarette smoking

          2. Concomitant serious disease such as diabetes, hypertension, coronary heart disease,
             other lung disease, cancer (other than skin cancer)

          3. Pregnancy or lack of contraception (hormonal or barrier)

          4. Allergies or intolerance to inhaled iloprost

          5. Participation in other ongoing research studies

          6. Any psychological problem that the investigators believe might interfere with the
             conduct of the investigation.

          7. Cigarette smoking

          8. History of bleeding disorder, use of anticoagulants

          9. Viral upper respiratory tract infection within the last 6 weeks

         10. Table of upper limit for steroid use Beclomethasone dipropionate HFA-MDI 480
             Budesonide DPI 1200 Flunisolide HFA-MDI 640 Fluticasone HFA-MDI 440 Fluticasone DPI
             500 Mometasone DPI 440 Triamcinolone 1500 (Table adapted from EPR3, daily doses are in
             micrograms) Asthmatics requiring higher doses of inhaled corticosteroids than those
             given above, or using oral steroids, leukotriene modifiers, mast cell stabilizers,
             omalizumab, theophylline or long acting beta agonists will be excluded.

         11. .Any screening laboratory blood test value outside the normal range will exclude the
             individual from the study, though an isolated abnormal value could be retested at an
             interval of no less than a week.
Clinical trial NCT00716794 (phase 1/phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: he3235
SMILES: C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C
Eligibility criteria:

        Main Inclusion Criteria:

          -  Patient is male and at least 18 years of age, at the time of screening;

          -  Patient has metastatic disease (any T, any N, M1);

          -  Patient has failed at least 1 taxane regimen; or Patient has symptomatic or
             asymptomatic CRPC and is chemotherapy-naïve

          -  Patient has histologically or cytologically confirmed adenocarcinoma of the prostate;

          -  Patient has progression of disease despite adequate hormone therapy, demonstrated by
             one of the following:

               -  PSA level of at least 2 ng/ml that has risen on at least 2 successive occasions,
                  at least 1 week apart.

               -  Evaluable disease progression by modified RECIST (Response Evaluation Criteria in
                  Solid Tumors) criteria;

               -  Progression of metastatic bone disease on bone scan with > 2 new lesions

          -  Patient has ECOG (Eastern Cooperative Oncology Group) performance status of 0-2;

        Main Exclusion Criteria:

          -  Patient has symptomatic parenchymal brain metastases or active epidural disease
             requiring whole-brain irradiation Treated epidural disease is allowed

          -  Patient has active infection;

          -  Patient having a history of clinically significant cardiovascular disease (such as
             CHF), clinically significant hepatic, respiratory or renal abnormalities;

          -  Patient who has any clinically significant abnormalities in laboratory results at
             screening

          -  Patient who has a history of clinically significant neurological or psychiatric
             condition;

        Additional criteria are applicable to expansion cohorts.
Clinical trial NCT00496782 (phase 1, status: terminated)
Conditions: hiv infections
ICD codes: Z21
Drugs: maraviroc
SMILES: CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
Reason stopped: 
    see detailed description
  
Eligibility criteria:

        Inclusion Criteria:

          -  ≥ 16 years of age (or minimum adult age as determined by local regulatory authorities
             or as dictated by local law) at the screening visit.

          -  Have an HIV RNA ≥ 1000 copies/mL, at screening.

          -  Subjects receiving another investigational antiretroviral compound through
             participation in a phase 3 or 4 clinical study are eligible to participate in this
             trial provided.

          -  That the 2 investigational agents are required to offer the subject a regimen with 2
             or 3 active antiretroviral drugs (i.e. one or fewer approved treatment is available to
             the subject due to prior resistance or intolerance),

          -  Neither protocol prohibits the use of the other antiretroviral agent, AND the dosing
             of the two agents when used together is known AND a letter from the Pfizer clinical
             pharmacologists for maraviroc identifies the dose of maraviroc to be used with other
             investigational agents.

          -  Based on screening genotypic resistance testing results the subject must be able to
             receive at least 3 active drugs other than maraviroc in the new OBT. This is defined
             as:

          -  Having three drugs considered susceptible by genotype interpretation (if etravirine
             will be used, fewer than 3 etravirine resistance mutations will be taken as etravirine
             susceptibility); or,

          -  Having two drugs considered susceptible by genotype interpretation (if etravirine will
             be used, fewer than 3 etravirine resistance mutations will be taken as etravirine
             susceptibility) and be willing to include raltegravir in the OBT not having used
             raltegravir in the past.

        Exclusion Criteria:

          -  Potentially life threatening (Grade 4) laboratory abnormality or medical condition.

          -  Severe hepatic impairment (Child-Pugh classification B or C).

          -  End stage renal disease or other disease states requiring dialysis therapy.
Clinical trial NCT00402116 (phase 1/phase 2, status: completed)
Conditions: glioblastoma, glioblastoma multiforme, gliosarcoma
ICD codes: L51.0, L51.8, L51.9
Drugs: enzastaurin, temozolomide
SMILES: CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have a histologically confirmed diagnosis of intracranial glioblastoma
             multiforme (GBM) or gliosarcoma (GS).

          -  Biopsy or resection must have been performed no more than 5 weeks prior to treatment.

          -  An MRI or CT scan must be obtained within 14 days prior to treatment.

          -  Patients must not have received prior drug therapy for brain tumors.

          -  Patients must have adequate organ function demonstrated by lab tests within 14 days
             prior to treatment.

        Exclusion Criteria:

          -  Patients will be excluded if unable to swallow tablets.

          -  Patients will be excluded if unable to discontinue use of enzyme inducing
             antiepileptic drugs or have been off of these agents less than 2 weeks prior to
             treatment (i.e. phenytoin (Dilantin®), carbamazepine, etc.).

          -  Patients will be excluded if have active infection.

          -  Patients will be excluded if have a significant medical illness that, in the
             investigator's opinion, cannot be adequately controlled with appropriate therapy or
             would compromise the patient's ability to tolerate this therapy.

          -  Patients will be excluded if they have concurrent therapy with an anticoagulant. If
             the patient requires anticoagulant therapy after starting treatment, the patient may
             remain on study but should be monitored carefully.
Clinical trial NCT01096030 (phase 1, status: completed)
Conditions: neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: regorafenib (stivarga, bay73-4506)
SMILES: O=[Zn]
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female Chinese subjects >/- 18 years

          -  Advanced, histologically or cytologically confirmed solid tumors

          -  Subjects malignancies must be refractory to standard treatment or have no standard
             therapy available, or the subject actively refused any treatment that would be
             regarded standard, and/or if, in the judgment of the investigator or his/her
             designated associate(s), experimental treatment is clinically and ethically
             acceptable.

          -  Eastern Cooperative Oncology Group performance status (ECOG-PS) 0-1;

          -  Adequate bone marrow, liver and renal function

          -  Life expectancy of at least 3 months

        Exclusion Criteria:

          -  Unstable/uncontrolled cardiac disease

          -  History of arterial or venous thrombotic or embolic events

          -  Malabsorption condition

          -  Severe renal impairment; persistent proteinuria >/= Grade 3

          -  Symptomatic metastatic brain or meningeal tumors

          -  Clinically significant bleeding >/=Grade 3 within 30 days before start of study
             medication.
Clinical trial NCT00466583 (phase 1, status: completed)
Conditions: carcinoma, lymphoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: intravenous ezn-2968 (anti-hif-1α lna as-odn)
SMILES: CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        Inclusion Criteria: Patients must meet all of the following criteria to be eligible for
        enrollment into the study.

          -  Histologically or cytologically confirmed diagnosis of advanced and/or metastatic
             solid tumor or lymphoma (Hodgkin's or non-Hodgkin's)

          -  Patients who have failed standard therapy and have no known effective therapy
             available to them

          -  Patients may have a tumor amenable to biopsy

          -  Measurable or evaluable disease.

          -  Age 18 years or older

        Exclusion Criteria: Patients meeting any of the following exclusion criteria will not be
        eligible for enrollment.

          -  Concurrent serious medical illness

          -  Known, clinically suspected, or history of central nervous system (CNS) tumor
             involvement

          -  Prior chemotherapy, immunotherapy, investigational agent, or other therapy used to
             treat the cancer within 4 weeks (6 weeks for prior treatment with mitomycin C or
             nitrosoureas) before the scheduled administration of EZN-2968. Luteinizing
             hormone-releasing hormone (LHRH) agonist therapy is permitted for patients with
             hormone refractory prostate cancer.
Clinical trial NCT00421811 (phase 1/phase 2, status: completed)
Conditions: neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: adh-1, melphalan
SMILES: N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed written informed consent

          -  Male and female patients > or = 18 years of age with diagnosis of melanoma for which
             treatment with Normothermic Isolated Limb Infusion (ILI) of melphalan would be
             appropriate

          -  Measurable disease

          -  Disease site(s) must be distal to the planned site of tourniquet placement

          -  Available for immunohistochemical testing of N-cadherin expression tumor tissue

          -  Adequate performance status and organ function, as evidenced by hematological and
             biochemical blood testing and ECG

        Exclusion Criteria:

          -  Receipt of ADH-1 prior to this clinical study (prior melphalan via ILI, is okay)

          -  Stage IV melanoma

          -  Chemotherapy, radiotherapy, or any other investigational drug within 4 weeks before
             study entry

          -  History of tumors that have shown clinically significant evidence of active bleeding
             within 12 weeks before study entry

          -  Stroke, major surgery, or other major tissue injury within 4 weeks before study entry

          -  Uncontrolled congestive heart failure, coronary artery disease, or life threatening
             arrhythmias; myocardial infarction within 12 months; significant electrocardiogram
             (ECG) abnormalities

          -  Allergic reaction to any therapeutic peptide or to melphalan
Clinical trial NCT01316341 (phase 1, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: bi10773, placebo, placebo, placebo, bi10773
SMILES: [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1
Eligibility criteria:

        Inclusion criteria:

          1. Chinese male and female patients with proven diagnosis of type 2 diabetes mellitus
             treated with diet and exercise only or on a maximum of two oral antidiabetic agents
             except thiazolidinediones with at least one agent taken at 50% of its maximum dose or
             less, unchanged for at least 12 weeks before randomization

          2. Glycosylated haemoglobin A1(HbA1c)<=8.5% and >=7.0% at screening,age>=21 and age<=70
             years (male and female patients),BMI>=19 and <=40 kg/m2

          3. Signed and dated written informed consent by date of Visit 1 in accordance with GCP
             and local legislation.

        Exclusion criteria:

          1. Patient who did not discontinue the antidiabetic treatment with insulin or glitazones,
             DPP-IV at least before 12 weeks before randomization

          2. Uncontrolled hyperglycaemia with a glucose level >240 mg/dl (>13.3 mmol/L) after an
             overnight fast at screening visit

          3. Clinically relevant concomitant diseases other than type 2 diabetes, hyperlipidaemia
             and medically treated hypertension, such as:

        4 Any late stage complication of diabetes (e.g. retinopathy, polyneuropathy, vegetative
        disorders, diabetic foot) 5 Renal insufficiency (calculated creatinine clearance < 80
        ml/min/1.73m²) 6 Cardiac insufficiency NYHA II-IV, myocardial infarction, other known
        cardiovascular diseases including hypertension > 160/95mmHg (measured at training visit and
        each of the timepoints of Day -1), stroke and TIA 7 Neurological disorders (such as
        epilepsy) or psychiatric disorders 8 Acute or relevant chronic infections (e.g. HIV,
        repeated urogenital infections) 9 Any gastrointestinal, hepatic, respiratory, endocrine or
        immunological disorder 10. History of relevant allergy/hypersensitivity (including allergy
        to drug or its excipients) 11. A marked baseline prolongation of QT/QTc interval (e.g., ECG
        demonstration of a QTc interval >450 ms ) at screening visit
Clinical trial NCT01562886 (phase 1, status: completed)
Conditions: hiv
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: rilpivirine
SMILES: CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1
Eligibility criteria:

        Inclusion Criteria:

          -  HIV-1 infected males subjects

          -  signed informed consent

          -  willing to switch therapy as per study protocol

          -  no previous exposure to rilpivirine

          -  plasma HIV RNA < 50 copies/mL at screening and on at least one other occasion over the
             last 3 months

          -  currently receiving a stable antiretroviral regimen comprising of TDF/FTC with
             nevirapine with nevirapine dosed either 200 mg twice daily or 400 mg once daily with
             no antiretroviral drug switches for at least 3 months

          -  no clinically-significant resistance documented on any prior HIV-1 genotypic
             resistance testing

          -  subjects in good health upon medical history, physical exam, and laboratory testing

          -  BMI above or equal to 18 and below 32

          -  Male subjects who are heterosexually active must use two forms of barrier
             contraception (e.g., condom and diaphragm) during heterosexual intercourse, from
             screening through completion of the study.

          -  Have local screening laboratory results (haematology and chemistry that fall within
             the normal range of the central laboratory's reference ranges unless the results have
             been determined by the Investigator to have no clinical significance

          -  No contraindications to having a lumbar puncture examination found on MRI of the brain

        Exclusion Criteria:

          -  current alcohol abuse or drug dependence

          -  positive urine drug of abuse screening

          -  active opportunistic infection or significant co-morbidities

          -  current disallowed concomitant medication (as listed in section 4.1.3)

          -  contraindication to MR examination or lumbar puncture examination

          -  recent head injury (in last 30 days) or chronic ongoing neurological diseases
Clinical trial NCT01165268 (phase 1, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin
SMILES: CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion criteria for T2DM

          -  Diagnosis of T2DM

          -  Must be on one of the following therapies: diet therapy alone, diet plus a
             sulfonylurea, diet plus metformin, or diet plus sulfonylurea plus metformin

          -  Subjects taking metformin, and/or sulfonylurea must be on a stable dose for at least 2
             months prior to study drug administration

          -  Must have a fasting plasma glucose concentration ≤ 200 mg/dl, and HbA1C ≤ 10%

        Inclusion criteria for healthy subjects:

          -  Healthy subjects (as determined by no clinically significant deviation from normal in
             medical history, physical examination, ECGs, and clinical laboratory determinations)

        Inclusion criteria for all subjects:

          -  Subjects with (eGFR ≥ 60 and ≤ 160 mL/min/1.73m² and urinary albumin excretion < 300
             mg/g creatinine)

          -  Body Mass Index (BMI) of 18 to 38 kg/m²

          -  Men and women, ages 18 to 65 years, inclusive

        Exclusion criteria for all subjects:

          -  Subjects with Type 1 Diabetes or uncontrolled Type 2 Diabetes Mellitus

          -  Subjects with T2DM with fasting plasma glucose > 200 mg/dL, healthy subjects with
             fasting plasma glucose > 105 mg/dL

          -  Subjects with T2DM with HbA1C > 10.0%, healthy subjects with HbA1C > 6.8%